Helmholtz Gemeinschaft


Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

Item Type:Article
Title:Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
Creators Name:Kapp-Schwoerer, S. and Weber, D. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Krönke, J. and Theis, F. and Rücker, F.G. and Teleanu, M.V. and Panina, E. and Jahn, N. and Herzig, J. and Kubanek, L. and Schrade, A. and Göhring, G. and Fiedler, W. and Kindler, T and Schroeder, T. and Mayer, K.T. and Lübbert, M. and Wattad, M. and Götze, K.S. and Horst, H.A. and Koller, E. and Wulf, G. and Schleicher, J. and Bentz, M. and Krauter, J. and Bullinger, L. and Krzykalla, J. and Benner, A. and Schlenk, R.F. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H and Döhner, K.
Abstract:Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1(mut)) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials. We determined NPM1(mut) transcript levels (TLs) by quantitative reverse-transcription polymerase chain reaction and evaluated the prognostic impact of NPM1(mut) MRD and the effect of gemtuzumab ozogamicin (GO) on NPM1(mut) TLs and the cumulative incidence of relapse (CIR) in patients with NPM1(mut) AML enrolled in the randomized phase 3 AMLSG 09-09 trial. A total of 3733 bone marrow (BM) samples and 3793 peripheral blood (PB) samples from 469 patients were analyzed. NPM1(mut) TL log(10) reduction ≥ 3 and achievement of MRD negativity in BM and PB were significantly associated with a lower CIR rate, after 2 treatment cycles and at end of treatment (EOT). In multivariate analyses, MRD positivity was consistently revealed to be a poor prognostic factor in BM and PB. With regard to treatment effect, the median NPM1(mut) TLs were significantly lower in the GO-Arm across all treatment cycles, resulting in a significantly greater proportion of patients achieving MRD negativity at EOT (56% vs 41%; P = .01). The better reduction in NPM1(mut) TLs after 2 treatment cycles in MRD positive patients by the addition of GO led to a significantly lower CIR rate (4-year CIR, 29.3% vs 45.7%, P = .009). In conclusion, the addition of GO to intensive chemotherapy in NPM1(mut) AML resulted in a significantly better reduction in NPM1(mut) TLs across all treatment cycles, leading to a significantly lower relapse rate.
Keywords:Acute Myeloid Leukemia, Bone Marrow, Disease-Free Survival, Gemtuzumab, Mutation, Neoplasm Proteins, Nuclear Proteins, Prospective Studies, Recurrence, Residual Neoplasm, Risk Factors, Survival Rate
Publisher:American Society of Hematology
Page Range:3041-3050
Date:24 December 2020
Official Publication:https://doi.org/10.1182/blood.2020005998
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library